Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR52 | Q9Y2T5 | 5/20 | 0.57 |
| ▸ | AURKA | O14965 | 9/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | BRAF | P15056 | 1/20 | 0.53 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.52 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3493237 | 0.83 | PHGDH (0.58) | GPR52AURKAALDH1A1MAPTKDM4E | |
| SCHEMBL3492011 | 0.81 | HDAC3 (0.57) | GPR52AURKAGAAHDAC3HDAC1 | |
| SCHEMBL3492215 | 0.81 | HDAC3 (0.54) | GPR52GAAHDAC3HDAC1HDAC2 | |
| SCHEMBL4238979 | 0.79 | AURKA (0.67) | AURKAGAABRAFALDH1A1MAPT | |
| SCHEMBL3492747 | 0.78 | ROCK1 (0.55) | ALDH1A1MAPTKDM4E | |
| SCHEMBL1518750 | 0.77 | AURKA (0.65) | AURKAGAAMAPTKDM4E | |
| SCHEMBL12590957 | 0.77 | AURKA (0.58) | GPR52AURKAGAAKDM4E | |
| SCHEMBL29646460 | 0.77 | GAA (0.68) | GAAHDAC3HDAC1HDAC2ALDH1A1 | |
| SCHEMBL1127884 | 0.77 | GAA (0.68) | GAAHDAC3HDAC1HDAC2ALDH1A1 | |
| SCHEMBL26186324 | 0.77 | AURKA (0.60) | AURKAGAABRAFHDAC3HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8492378-B2 | GSK-3β inhibitor | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-07-23 | — | — | US | disclosed |
| US-20100069381-A1 | GSK-3BETAINHIBITOR | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069381-A1 | GSK-3BETAINHIBITOR | GSK3B, GSK3A, GSKIP | GPR52 4298/4885AURKA 903/4885GAA 1403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.